R2R01: A Potent Long-Acting RXFP1 Peptide Agonist in Phase 2 Development for Cardiovascular and Renal Disorders

About this poster

R2R01 is a novel long-acting peptide agonist of RXFP1, developed as a potential therapy for cardiovascular and renal disorders. Building on the therapeutic promise of the natural hormone Relaxin-2, over 800 analogues were explored to overcome metabolic and safety limitations, resulting in potent single-chain agonists with enhanced stability and prolonged half-life. This poster outlines the discovery journey leading to R2R01, its distinctive pharmacological profile, and its advancement into Phase 2 clinical development.